At October’s GRx+Biosims meeting, we sat down with Joshua Salsi to discuss how a company like Biocon Biologics is facing the rapidly evolving regulatory and biosimilar market access environment. The conversation involved the difficulties in making strategic decisions about molecules that may launch many years in the future, as well as the sustainability of the industry through challenging times.